Holen Sie sich die Stockscreener-App
4.5803
7.14%
0.3103
Schlusskurs vom Vortag:
$4.27
Offen:
$4.29
24-Stunden-Volumen:
4.38M
Relative Volume:
0.70
Marktkapitalisierung:
$1.37B
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-8.8083
EPS:
-0.52
Netto-Cashflow:
$-121.38M
1W Leistung:
+11.04%
1M Leistung:
+14.09%
6M Leistung:
+45.70%
1J Leistung:
+71.35%
1-Tages-Spanne:
$4.27
$4.7699
1-Wochen-Bereich:
$3.93
$5.01
52-Wochen-Spanne:
$1.8906
$5.82
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Vergleichen Sie ABCL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.575 | 1.34B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.78 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.70 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.71 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.33 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.20 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
AbCellera Biologics stock rating maintained at Hold by Benchmark - Investing.com
AbCellera to Participate at Upcoming Investor Conferences in September 2025 - BioSpace
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript - AOL.com
AbCellera Biologics Earnings Call: Clinical Progress and Financial Insights - TipRanks
AbCellera to Present at Upcoming Investor Conferences in September - AInvest
AbCellera to Participate at Upcoming Investor Conferences in September - The Globe and Mail
Industry Analysts Just Made A Huge Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Revenue Forecasts - Yahoo Finance
AbCellera's Q2 2025 Earnings Call: Unpacking Contradictions in Regulatory Focus, Dosing Strategies, and Market Expansion - AInvest
Will AbCellera Biologics Inc. benefit from seasonalityRocket Stock Alert Service - mustnews.co.kr
AbCellera Biologics Advances Clinical Trials and Revenue Growth - TipRanks
AbCellera reports Q2 EPS (12c), consensus (16c) - MSN
AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Call Transcript - Insider Monkey
AbCellera Biologics 2025 Q2 Earnings Net Loss Narrows Slightly - AInvest
AbCellera Biologics Reports Q2 2025 Financial Results - The Globe and Mail
AbCellera Biologics Soars 19.34% on Q2 Revenue Surge - AInvest
AbCellera Biologics Inc. shares rise 15.80% premarket after reporting Q2 revenue beat estimates and beginning Phase 1 clinical trial for ABCL635. - AInvest
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... - Yahoo Finance
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... By GuruFocus - Investing.com Canada
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - BioSpace
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating - TipRanks
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Canadian biotech firm AbCellera Q2 revenue beats estimates - MarketScreener
AbCellera soars as revenue more than doubles estimates By Investing.com - Investing.com Australia
Abcellera Biologics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
AbCellera Biologics: A Turning Point in Biotech's Antibody Revolution - AInvest
AbCellera begins dosing in phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
Earnings Flash (ABCL) AbCellera Biologics Inc. Reports Q2 Revenue $17.1M - MarketScreener
Senseonics Holdings Inc Q2 Revenue Reaches $6.6 Million, EPS Loss at $0.02, Meets Analyst Expectations - AInvest
Is AbCellera Biologics Inc. stock overvalued or undervaluedOutstanding yields - Jammu Links News
Is AbCellera Biologics Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
What are AbCellera Biologics Inc. company’s key revenue driversOver 200% growth - Jammu Links News
What is the risk reward ratio of investing in AbCellera Biologics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
Why is AbCellera Biologics Inc. stock attracting strong analyst attentionMarket-beating returns - Jammu Links News
What is the dividend policy of AbCellera Biologics Inc. stockConsistently superior profits - Jammu Links News
How volatile is AbCellera Biologics Inc. stock compared to the marketBuild a diversified portfolio for risk management - Jammu Links News
How many analysts rate AbCellera Biologics Inc. as a “Buy”Achieve breakthrough financial results - Jammu Links News
How does AbCellera Biologics Inc. generate profit in a changing economySuperior profit margins - Jammu Links News
What drives AbCellera Biologics Inc. stock priceMarket-leading growth rates - Jammu Links News
Does AbCellera Biologics Inc. stock perform well during market downturnsAchieve explosive financial results today - Jammu Links News
Is AbCellera Biologics Inc. a good long term investmentInvest smarter with daily trading signals - Jammu Links News
What analysts say about AbCellera Biologics Inc. stockInvest confidently with professional market insights - Jammu Links News
When is AbCellera Biologics Inc. stock expected to show significant growthAchieve rapid financial growth with smart picks - Jammu Links News
Should I hold or sell AbCellera Biologics Inc. stock in 2025Capitalize on fast-moving trading opportunities - Jammu Links News
What are the latest earnings results for AbCellera Biologics Inc.Beginner Investor Alerts For Fast Growth - Jammu Links News
Piper Sandler Reiterates a Buy Rating on AbCellera Biologics (ABCL) - MSN
AbCellera Biologics Institutional Ownership: Sensitivity to Trading Actions Amid Market Cap Decline - AInvest
Institutional owners may ignore AbCellera Biologics Inc.'s (NASDAQ:ABCL) recent US$125m market cap decline as longer-term profits stay in the green - Yahoo Finance
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):